MDAI Earnings

MDAI reported its earnings on 2026-03-24, showcasing a revenue of 3.85M against an estimate of 2.91M, resulting in a 32.27% surprise. The EPS was -0.11, surpassing the expected -0.12 by 8.33%. The stock experienced a -6.67% price change on the earnings day and a -11.52% change over the next five days, reflecting market reactions to the results.

Following MDAI's earnings announcement on 2026-03-24, the stock price moved by -6.67% on the day of the release. Over the subsequent five days, it saw a -11.52% change. Historically, MDAI's stock price tends to shift by an average of 4.18% in the 10 days leading up to earnings and -1.85% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate MDAI's annual revenue to reach 4.31M, while the EPS is projected at -0.02. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MDAI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MDAI's stock price typically moves by 4.18% in the 10 days before its earnings and -1.85% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.02 and revenue of 4.31M.

The earnings call summary shows mixed signals: improved net income and cash position are positive, but declining gross margins and R&D revenue are concerns. The Q&A section highlights strategic planning for commercialization but lacks specific details, which raises uncertainty. The absence of guidance adjustments and unclear management responses further contribute to a neutral sentiment. Overall, while there are positive elements, the uncertainties and lack of immediate catalysts keep the stock reaction neutral.